Medvi vs Brello: Comparing Two GLP-1 Telehealth Programs

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we unpack GLP-1 therapies, weight-management protocols, and the inherited biology behind every metabolic choice. Browse all Peptides & GLP-1 education

Full head-to-head: PlexusDx vs MEDVi →

This is an independent editorial comparison. PlexusDx holds no commercial relationship with Medvi or Brello, and it involves no affiliate links or compensation.

Readers comparing Medvi and Brello want a straight look at how two telehealth GLP-1 brands stack up. This piece outlines how each is structured, where they overlap, and the genetic variable neither addresses. As of April 2026 the market holds dozens of options; this comparison stays focused on the two named in the query, with balanced framing rather than a verdict.

Medvi and Brello: two telehealth paths

Both Medvi and Brello operate as telehealth-plus-compounded-pharmacy GLP-1 services, so at a high level they share a category. Each pairs a virtual clinical evaluation with provider-issued prescriptions and dispenses either FDA-approved branded GLP-1 products or compounded semaglutide and tirzepatide through licensed pharmacy pathways. The meaningful differences show up in the details of each brand's model, not in the underlying category.

Where Medvi positions itself

Medvi (Medvi Wellness) runs a telehealth-and-compounded-pharmacy program built around virtual evaluation, provider-issued prescriptions, and GLP-1 dispensing through brand-name or compounded pathways. Its current program structure, medication options, and pricing are documented on Medvi's official website, which is the authoritative place to confirm what the program includes at the time you read this.

Where Brello positions itself

Brello (Brello Health) likewise operates a telehealth-plus-compounded-pharmacy GLP-1 program. Its program tiers, medication choices, and pricing vary and are subject to change, so the current specifics should be confirmed on Brello's official website rather than inferred. Structurally it occupies the same telehealth GLP-1 lane as Medvi, with distinctions living in provider model, dispensing pathway, and subscription design.

Comparing dispensing and provider models

When two programs sit in the same category, the practical comparison points are dispensing pathway (FDA-approved brand versus compounded), provider type, subscription structure, and price. Across the telehealth GLP-1 market as of April 2026, total monthly spend commonly spans roughly $200 to $700 or more including program fees, medication, and compounded dispensing where applicable. Rather than rely on figures that may be stale, verify each brand's current pricing on its own page before deciding.

Trial evidence sits with the compound, not the brand

Neither brand determines the pharmacology. The class evidence comes from STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Effect sizes vary by compound, dose, and population. A telehealth program's mechanism is driven by the compound it prescribes, not by the platform delivering it.

The genetic factor neither platform maps

What neither Medvi nor Brello addresses is the inherited biology underneath a GLP-1 response. Variation in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor gene every GLP-1 compound targets), MC4R (a satiety and energy-balance receptor), and TCF7L2 (linked to glucose regulation and GLP-1 secretion) maps the metabolic terrain a compound acts on. These pathway-level markers do not predict response, but they describe the biology behind any prescription.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, mapping FTO, MC4R, and TCF7L2 before any protocol. Test before you invest, then bring that context into a provider conversation.

Not affiliated: PlexusDx is not affiliated with Medvi or Brello and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Disclaimer: Educational content only. PlexusDx is unaffiliated with Medvi and Brello and holds no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, so this compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways; it does not predict response to any medication. Consult a qualified healthcare provider before beginning a peptide protocol.

See the PlexusDx approach: review the Weight Management Protocols, or start upstream with the Precision Peptide Genetic Test.

Keep exploring evidence-based GLP-1 and peptide guidance in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Frequently Asked Questions

Is Medvi or Brello the better choice?

Neither is objectively better; both operate in the GLP-1 telehealth category with comparable structures. What differs is medication options, pricing tiers, and provider model. Individual fit depends on cost, coverage, and program mechanics. Review each brand's own details before deciding rather than assuming one leads across the board.

How do Medvi and Brello differ on medication?

Both can prescribe GLP-1 receptor agonists through telehealth. Their differences fall in dispensing pathway (FDA-approved brand versus compounded), subscription structure, and provider type. Neither program determines the underlying pharmacology, which is driven by the compound itself rather than by the telehealth platform delivering the prescription to you.

Do Medvi and Brello take insurance?

Compounded GLP-1 telehealth programs commonly operate cash-pay and do not bill insurance, so the listed price is generally what you pay. Coverage for compounded products is uncommon. Confirm each brand's payment model on its own site, since billing arrangements and any insurance handling can differ between programs.

How does PlexusDx compare with Medvi and Brello?

PlexusDx pairs its semaglutide and tirzepatide Weight Management Protocols with the Precision Peptide Genetic Test. The differentiator is pathway-level genetic insight mapping FTO, MC4R, context not offered at Medvi, Brello, or most GLP-1 telehealth programs alongside the medication itself.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.